keyword
MENU ▼
Read by QxMD icon Read
search

Direct antiviral agents

keyword
https://www.readbyqxmd.com/read/28936400/diminishing-use-of-liver-biopsy-among-liver-transplant-recipients-for-hepatitis-c
#1
Elizabeth Aby, Melissa A Jimenez, Jonathan F Grotts, Vatche Agopian, Samuel W French, Ronald W Busuttil, Sammy Saab
Background and Aims: Hepatitis C virus (HCV) cirrhosis is the leading indication for liver transplantation in the United States and recurrent HCV following liver transplantation is a major cause of allograft loss and mortality. Liver biopsies are commonly used to identify recurrent HCV and determine the need for antiviral therapy. The introduction of direct-acting antiviral agents (DAAs) has changed the management of recurrent HCV infection. This study aimed to describe the role of liver biopsies in liver transplant recipients with HCV after the introduction of DAAs...
September 28, 2017: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/28927498/drug-treatment-for-chronic-hepatitis-c-infection-and-cancer-risk
#2
Marcus-Alexander Wörns, Peter Robert Galle, Stefan Zeuzem, Peter Schirmacher, Michael Manns, Arndt Vogel
BACKGROUND: In patients with chronic hepatitis C infection, a sustained virologic response (SVR) to interferon-based therapy markedly decreases the incidence of hepatocellular carcinoma (HCC) over the long term. This is also true for patients who have hepatic cirrhosis, as well as for those with HCC-with or without cirrhosis-who have undergone resection or ablation with curative intent. Recent publications, however, have reported a higher incidence of HCC among patients in both of these subgroups who were treated with direct antiviral agents (DAA) rather than interferon-based therapy...
September 4, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28926562/generics-for-the-treatment-of-hepatitis-c-in-monoinfected-and-hiv-coinfected-patients-pros-and-cons
#3
Dario Cattaneo, Alessandro Fossati, Chiara Resnati, Massimo Galli, Cristina Gervasoni
The treatment of hepatitis C virus in monoinfected and HIV-coinfected patients has greatly changed over recent years as a result of the introduction of direct-acting antiviral agents (DAAs), which have revolutionized clinical outcomes and led to sustained virological response rates above 90-95%. The discovery of new molecules and the subsequent competition between pharmaceutical companies, together with the negotiated price policies pursued by many national health systems, have led to a gradual reduction in the cost of DAAs, and expand their use to an increasing number of patients, including those with mild liver damage...
September 19, 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28903508/effect-of-paritaprevir-ritonavir-ombitasvir-dasabuvir-and-ledipasvir-sofosbuvir-regimens-on-survival-compared-with-untreated-hepatitis-c-virus-infected-persons-results-from-erchives
#4
Adeel Ajwad Butt, Peng Yan, Tracey G Simon, Abdul-Badi Abou-Samra
Background: Interferon-based regimens are associated with a substantial survival benefit for persons infected with hepatitis C virus (HCV). Survival data with direct-acting antiviral agents are not available. We conducted this study to quantify the effect of paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) and ledipasvir/sofosbuvir (LDV/SOF) regimens upon mortality. Methods: In the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES), a well-established national cohort of HCV-infected Veterans, we identified HCV-infected persons initiated on PrOD or LDV/SOF, excluding those with human immunodeficiency virus, hepatitis B surface antigen positivity, hepatocellular carcinoma, or missing HCV RNA or FIB-4 scores...
September 15, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28901852/recent-advancement-of-direct-acting-antiviral-agents-daas-in-hepatitis-c-therapy
#5
Debasis Das, Mayank Pandya
Hepatitis C virus (HCV) infection is a major health burden worldwide. Approximately, 170-200 million individuals are chronically infected worldwide and a quarter of these patients are at increased risk of developing liver cirrhosis, hepatocellular carcinoma and even liver failure. A complete eradication of the virus is one of the most important treatment goal for antiviral research. In 2011, the first-generation protease inhibitors boceprevir (BOC) telaprevir (TVR) have been approved by FDA as the direct-acting antiviral agents...
September 12, 2017: Mini Reviews in Medicinal Chemistry
https://www.readbyqxmd.com/read/28898563/direct-acting-antiviral-agents-based-regimen-for-hcv-recurrence-after-combined-liver-kidney-transplantation-results-from-the-anrs-co23-cupilt-study
#6
Sébastien Dharancy, Audrey Coilly, Claire Fougerou-Leurent, Christophe Duvoux, Nassim Kamar, Vincent Leroy, Albert Tran, Pauline Houssel-Debry, Valérie Canva, Christophe Moreno, Filoména Conti, Jérome Dumortier, Vincent Di Martino, Sylvie Radenne, Victor De Ledinghen, Louis D'Alteroche, Christine Silvain, Camille Besch, Philippe Perré, Danielle Botta-Fridlund, Claire Francoz, François Habersetzer, Hélène Montialoux, Armand Abergel, Maryline Debette-Gratien, Alexandra Rohel, Emilie Rossignol, Didier Samuel, Jean-Charles Duclos-Vallée, Georges-Philippe Pageaux
HCV infection is associated with reduced patient survival following combined liver-kidney transplantation (LKT). The aim of this study was to assess the efficacy and safety of second generation direct active antiviral (DAAs) in this difficult-to-treat population. The ANRS CO23 CUPILT study is a prospective cohort including transplant recipients with recurrent HCV treated with DAAs. The present work focused on recipients with recurrent HCV following LKT. The study population included 23 patients. All patients received at least one NS5B inhibitor (Sofosbuvir) in their antiviral regimen an average of 90 months after LKT...
September 12, 2017: American Journal of Transplantation
https://www.readbyqxmd.com/read/28898286/structural-investigation-of-c6-36-and-vero-cell-cultures-infected-with-a-brazilian-zika-virus
#7
Debora Ferreira Barreto-Vieira, Fernanda Cunha Jácome, Marcos Alexandre Nunes da Silva, Gabriela Cardoso Caldas, Ana Maria Bispo de Filippis, Patrícia Carvalho de Sequeira, Elen Mello de Souza, Audrien Alves Andrade, Pedro Paulo de Abreu Manso, Gisela Freitas Trindade, Sheila Maria Barbosa Lima, Ortrud Monika Barth
Zika virus (ZIKV) is a member of the flavivirus genus, and its genome is approximately 10.8 kilobases of positive-strand RNA enclosed in a capsid and surrounded by a membrane. Studies on the replication dynamics of ZIKV are scarce, which limits the development of antiviral agents and vaccines directed against ZIKV. In this study, Aedes albopictus mosquito lineage cells (C6/36 cells) and African green monkey kidney epithelial cells (Vero cells) were inoculated with a ZIKV sample isolated from a Brazilian patient, and the infection was characterized by immunofluorescence staining, phase contrast light microscopy, transmission electron microscopy and real-time RT-PCR...
2017: PloS One
https://www.readbyqxmd.com/read/28887168/hcv-eradication-induced-by-direct-acting-antiviral-agents-reduces-the-risk-of-hepatocellular-carcinoma
#8
George N Ioannou, Pamela K Green, Kristin Berry
BACKGROUND AND AIMS: It is unclear whether direct-acting antiviral (DAA) treatment-induced sustained virologic response (SVR) reduces the risk of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) infection. We aimed to determine the impact of DAA-induced SVR on HCC risk. METHODS: We identified 62,354 patients who initiated antiviral treatment in the Veterans Affairs (VA) national healthcare system from 1/1/1999 to 12/31/2015, including 35,871 (58%) interferon-only regimens, 4535 (7...
September 5, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28886313/susceptibility-of-herpes-simplex-virus-type-1-to-monoterpenes-thymol-carvacrol-p-cymene-and-essential-oils-of-sinapis-arvensis-l-lallemantia-royleana-benth-and-pulicaria-vulgaris-gaertn
#9
J Sharifi-Rad, B Salehi, P Schnitzler, S A Ayatollahi, F Kobarfard, M Fathi, M Eisazadeh, M Sharifi-Rad
In recent years, with increased the prevalence of viral infections and having no specific for  their treatment  and also the continuous appearance of resistant viral strains, the finding of novel antiviral agents is necessary. In this study, monoterpenes of thymol, carvacrol, p-cymene and essential oils from Sinapis arvensis L., Lallemantia royleana Benth. and Pulicaria vulgaris Gaertn. were screened for their inhibitory effect against herpes simplex virus type 1 (HSV-1) in vitro on Vero cell line CCL-81-ATCC using a plaque reduction assay...
August 30, 2017: Cellular and Molecular Biology
https://www.readbyqxmd.com/read/28883690/direct-acting-antiviral-agents-against-hepatitis-c-virus-and-lipid-metabolism
#10
EDITORIAL
Tatsuo Kanda, Mitsuhiko Moriyama
Hepatitis C virus (HCV) infection induces steatosis and is accompanied by multiple metabolic alterations including hyperuricemia, reversible hypocholesterolemia and insulin resistance. Total cholesterol, low-density lipoprotein-cholesterol and triglyceride levels are increased by peginterferon and ribavirin combination therapy when a sustained virologic response (SVR) is achieved in patients with HCV. Steatosis is significantly more common in patients with HCV genotype 3 but interferon-free regimens are not always effective for treating HCV genotype 3 infections...
August 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28882564/searching-for-synergy-identifying-optimal-antiviral-combination-therapy-using-hepatitis-c-virus-hcv-agents-in-a-replicon-system
#11
Justin J Pomeroy, George L Drusano, Jaime L Rodriquez, Ashley N Brown
Direct acting antiviral agents (DAAs) are potent inhibitors of Hepatitis C virus (HCV) that have revolutionized the treatment landscape for this important viral disease. There are currently four classes of DAAs that inhibit HCV replication via distinct mechanisms of action: nonstructural protein (NS) 3/4a protease inhibitors, NS5A inhibitors, NS5B nucleoside polymerase inhibitors, and NS5B non-nucleoside polymerase inhibitors. Combination therapy with two or more DAAs has great potential to further enhance antiviral potency...
September 4, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28874853/editorial-direct-antiviral-agents-eliminate-the-age-barrier-to-treatment-of-chronic-hepatitis-c
#12
EDITORIAL
Raymond S Koff
Interferon-based therapy for chronic hepatitis C in elderly patients, who are at greatest risk for advanced disease, resulted in low sustained virologic response rates, poor tolerability, a significant frequency of adverse events leading to treatment discontinuation, and the occasional precipitation of hepatic decompensation. In contrast, in the era of direct-acting antiviral therapy, age is no longer a predictor of response rates in those with or without cirrhosis and adverse events are much less frequent...
September 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28874040/direct-acting-antiviral-agents-in-korean-patients-with-chronic-hepatitis-c-and-hemophilia-who-are-treatment-na%C3%A3-ve-or-treatment-experienced
#13
Hyun Woong Lee, Ki Young Yoo, Joung Won Won, Hyung Joon Kim
Background/Aims: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. Methods: Patients (n=30) were enrolled between September 2015 and April 2016. Twenty-six patients were genotype 1 (1b, n=21; 1a, n=5) and four patients were genotype 2a/2b. Among 21 patients with genotype 1b, Y93H resistance-associated variants (RAVs) were detected in three patients (14.3%). We evaluated sustained virologic response (SVRs) at 12 weeks, as well as relapse and safety...
September 15, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28873225/chronic-hepatitis-c-increases-the-risk-of-chronic-kidney-disease-ckd-while-effective-hcv-treatment-decreases-the-incidence-of-ckd
#14
Haesuk Park, Chao Chen, Wei Wang, Linda Henry, Robert L Cook, David R Nelson
We aimed to assess the risk of chronic kidney disease (CKD) in chronic hepatitis C virus (HCV) infected patients and the incidence reduction of CKD after receipt of HCV treatment. We also evaluated the risk of membranoproliferative glomerulonephritis (MPGN) and cryoglobulinemia in chronic HCV patients. A retrospective cohort analysis of the Truven Health MarketScan Database (2008-2015) in the United States was conducted. In a cohort of 56,448 HCV-infected patients and propensity score (1:3) matched 169,344 non-HCV patients, we examined the association of HCV infection with the incidence of CKD...
September 5, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28868829/factors-associated-with-improved-glycemic-control-by-direct-acting-antiviral-agent-treatment-in-egyptian-type-2-diabetes-mellitus-patients-with-chronic-hepatitis-c-genotype-4
#15
Alaaeldin Abdelsalam Dawood, Mohamed Zakarya Nooh, Ayman Abdelhaleem Elgamal
BACKGROUND: The association of chronic hepatitis C virus (HCV) infection with type 2 diabetes mellitus (T2DM) was first reported in 1994. Little is known about the effect of direct-acting antiviral agents (DAAs) on glycemic control in T2DM patients. The aim of the present study was to evaluate the factors associated with improved glycemic control (IGC) by DAA treatment in Egyptian T2DM patients with chronic HCV genotype 4 infection. METHODS: This study included 460 T2DM patients with chronic HCV genotype 4 infection...
August 2017: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/28856597/chemical-genetics-based-development-of-small-molecules-targeting-hepatitis-c-virus
#16
REVIEW
Guanghai Jin, Jisu Lee, Kyeong Lee
Hepatitis C virus (HCV) infection is a major worldwide problem that has emerged as one of the most significant diseases affecting humans. There are currently no vaccines or efficient therapies without side effects, despite today's advanced medical technology. Currently, the common therapy for most patients (i.e. genotype 1) is combination of HCV-specific direct-acting antivirals (DAAs). Up to 2011, the standard of care (SOC) was a combination of peg-IFNα with ribavirin (RBV). After approval of NS3/4A protease inhibitor, SOC was peg-IFNα and RBV with either the first-generation DAAs boceprevir or telaprevir...
August 30, 2017: Archives of Pharmacal Research
https://www.readbyqxmd.com/read/28851700/model-based-projection-of-health-and-economic-effects-of-screening-for-hepatitis-c-in-canada
#17
William W L Wong, Aysegul Erman, Jordan J Feld, Murray Krahn
BACKGROUND: Because most hepatitis C virus (HCV) infections are asymptomatic and often unrecognized, screening for hepatitis C has been proposed as a plausible public health strategy. We examined the health and economic consequences of a selective one-time hepatitis C screening program for specific populations in the context of current treatment patterns. METHODS: We used a state-transition model to evaluate 2 general strategies: no screening, and screen and treat with direct-acting antiviral agents...
August 25, 2017: CMAJ Open
https://www.readbyqxmd.com/read/28845110/prioritization-for-interferon-free-regimens-and-potential-drug-interactions-of-current-direct-acting-anti-hepatitis-c-agents-in-routine-clinical-practice
#18
Μargarita Papatheodoridi, George N Dalekos, John Goulis, Spilios Manolakopoulos, Christos Triantos, Kalliopi Zachou, Argyro Koukoufiki, Αnastasia Κourikou, Κonstantinos Ζisimopoulos, Christos Τsoulas, George V Papatheodoridis
BACKGROUND: We determined the proportions of patients with chronic hepatitis C (CHC) in association with possible prioritized indications for interferon-free regimens and the use of co-medications with potential drug-drug interactions (DDIs). METHODS: Five hundred consecutive mono-infected CHC patients seen in 2015 at 5 Greek centers were included. Priorities for interferon-free regimens were based on liver disease severity, contraindication(s) for interferon and prior interferon-treatment failure...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/28838786/improved-outcomes-in-hcv-patients-following-liver-transplantation-during-the-era-of-direct-acting-antiviral-agents
#19
George Cholankeril, Andrew A Li, Katherine L March, Eric R Yoo, Donghee Kim, Heather Snyder, Stevan A Gonzalez, Zobair M Younossi, Aijaz Ahmed
No abstract text is available yet for this article.
August 31, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28835817/do-we-really-need-more-evidence-to-use-hepatitis-c-positive-donor-kidney-more-liberally
#20
Kiran Joglekar, James D Eason, Miklos Z Molnar
The number of patients listed active for kidney transplantation has continued to rise over the last 10 years, leading to significantly increased wait-list time for patients awaiting kidney transplantation in the USA. This increased demand has led to a supply-demand mismatch and should prompt clinicians to seek timely solutions to improve access to available organs. Hepatitis C virus positive [HCV(+)] kidneys continue to be discarded without clear evidence that they lead to poor outcomes in the current era of highly efficacious HCV treatment with direct-acting antiviral agents (DAAs)...
August 2017: Clinical Kidney Journal
keyword
keyword
12534
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"